# Oncologic Drugs Advisory Committee; Cancellation
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
**SUMMARY:**
The meeting of the Oncologic Drugs Advisory Committee scheduled for October 6, 2009, is cancelled. This meeting was announced in the *Federal Register* of August 25, 2009 (74 FR 42907). The October 6, 2009, Oncologic Drugs Advisory Committee meeting was to discuss ApoPharma, Inc.'s new drug application (NDA) 021-825 for proposed trade name FERRIPROX (deferiprone) film-coated tablets. This meeting has been cancelled to allow time for FDA to review and resolve several outstanding issues. The agency intends to continue evaluating NDA 021-825 and, as needed, may schedule an advisory committee meeting in the future.
**FOR FURTHER INFORMATION CONTACT:**
Nicole Vesely, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-6793, FAX: 301-827-6776, e-mail: *[email protected]* , or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512542. Please call the Information Line for up-to-date information on this meeting.
Dated: September 28, 2009.
David Horowitz,
Assistant Commissioner for Policy.